Paga (Bms), ‘deucravacitinib oral therapy more for psoriasis patients’

“The green light from Aifa to the reimbursement of a new oral therapy (deucravacitinib) for moderate or severe psoriasis is a very important result. This molecule allows us to treat and try to manage symptoms for as long as possible and have new opportunities when previous therapies fail to maintain the response. Deucravacitinib is the first oral therapy to act on the TIK2 protein, which plays an important role in regulating the immune system. The four-year data confirm both the duration of the response and the safety profile, it is a very well tolerated molecule”. This was stated by Cosimo Paga, executive country medical director Bristol Myers Squibb, during the press conference announcing the green light from Aifa to the reimbursement of deucravacitinib for the treatment of moderate to severe psoriasis.